{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:47:43Z","timestamp":1794008863882,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["Ministry of Food and Drug Safety"],"award-info":[{"award-number":["Ministry of Food and Drug Safety"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2019R1A2C1004582"],"award-info":[{"award-number":["NRF-2019R1A2C1004582"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12272-023-01448-z","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T11:15:01Z","timestamp":1682421301000},"page":"438-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects"],"prefix":"10.1007","volume":"46","author":[{"given":"Pureum","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Keun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon-Gon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-1981","authenticated-orcid":false,"given":"Seok-Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ik","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Woo","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"issue":"4","key":"1448_CR1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1365-2125.2005.02448.x","volume":"60","author":"JW Bae","year":"2005","unstructured":"Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY (2005) Allele and genotype frequencies of CYP2C9 in a korean population. Br J Clin Pharmacol 60(4):418\u2013422. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02448.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1448_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2125.2010.03853.x","volume":"71","author":"JW Bae","year":"2011","unstructured":"Bae JW, Choi CI, Jang CG, Lee SY (2011a) Effects of CYP2C9*1\/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 71(4):550\u2013555. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03853.x","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1448_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/aps.2011.100","volume":"32","author":"JW Bae","year":"2011","unstructured":"Bae JW, Choi CI, Kim MJ, Oh DH, Keum SK, Park JI, Kim BH, Bang HK, Oh SG, Kang BS, Park HJ, Kim HD, Ha JH, Shin HJ, Kim YH, Na HS, Chung MW, Jang CG, Lee SY (2011) Frequency of CYP2C9 alleles in koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 32(10):1303\u20131308. https:\/\/doi.org\/10.1038\/aps.2011.100","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"1448_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5414\/cp201467","volume":"50","author":"JW Bae","year":"2012","unstructured":"Bae JW, Choi CI, Lee HI, Lee YJ, Jang CG, Lee SY (2012) Effects of CYP2C9*1\/*3 and *1\/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. Int J Clin Pharmacol Ther 50(9):683\u2013689. https:\/\/doi.org\/10.5414\/cp201467","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"1448_CR5","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s12272-020-01293-4","volume":"43","author":"JW Bae","year":"2020","unstructured":"Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207\u20131213. https:\/\/doi.org\/10.1007\/s12272-020-01293-4","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1448_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/gim.2016.87","volume":"19","author":"KE Caudle","year":"2017","unstructured":"Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM (2017) Standardizing terms for clinical pharmacogenetic test results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC). Genet Med 19(2):215\u2013223. https:\/\/doi.org\/10.1038\/gim.2016.87","journal-title":"Genet Med"},{"issue":"2","key":"1448_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bcpt.12992","volume":"123","author":"Y Chen","year":"2018","unstructured":"Chen Y, Chen L, Zhang H, Huang S, Xiong Y, Xia C (2018) Interaction of sulfonylureas with liver uptake transporters OATP1B1 and OATP1B3. Basic Clin Pharmacol Toxicol 123(2):147\u2013154. https:\/\/doi.org\/10.1111\/bcpt.12992","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"1448_CR8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12272-021-01357-z","volume":"44","author":"CK Cho","year":"2021","unstructured":"Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021a) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res 44(11):1037\u20131049. https:\/\/doi.org\/10.1007\/s12272-021-01357-z","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1448_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s12272-021-01361-3","volume":"44","author":"CK Cho","year":"2021","unstructured":"Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY (2021b) Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Arch Pharm Res 44(12):1076\u20131090. https:\/\/doi.org\/10.1007\/s12272-021-01361-3","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1448_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12272-022-01388-0","volume":"45","author":"CK Cho","year":"2022","unstructured":"Cho CK, Kang P, Park HJ, Ko E, Mu CY, Lee YJ, Choi CI, Kim HS, Jang CG, Bae JW, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Arch Pharm Res 45(5):352\u2013366. https:\/\/doi.org\/10.1007\/s12272-022-01388-0","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1448_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12272-022-01423-0","volume":"46","author":"CK Cho","year":"2023","unstructured":"Cho CK, Byeon JY, Kang P, Park HJ, Ko E, Mu CY, Jang CG, Lee SY, Lee YJ (2023a) Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects. Arch Pharm Res 46(2):111\u2013116. https:\/\/doi.org\/10.1007\/s12272-022-01423-0","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1448_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12272-022-01422-1","volume":"46","author":"CK Cho","year":"2023","unstructured":"Cho CK, Byeon JY, Kang P, Park JI, Jang CG, Lee SY, Choi CI, Bae JW, Lee YJ (2023b) Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone. Arch Pharm Res 46(1):59\u201364. https:\/\/doi.org\/10.1007\/s12272-022-01422-1","journal-title":"Arch Pharm Res"},{"issue":"6","key":"1448_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1742-7843.2011.00751.x","volume":"109","author":"CI Choi","year":"2011","unstructured":"Choi CI, Kim MJ, Jang CG, Park YS, Bae JW, Lee SY (2011) Effects of the CYP2C9*1\/*13 genotype on the pharmacokinetics of lornoxicam. Basic Clin Pharmacol Toxicol 109(6):476\u2013480. https:\/\/doi.org\/10.1111\/j.1742-7843.2011.00751.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1448_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00228-011-1098-0","volume":"68","author":"CI Choi","year":"2012","unstructured":"Choi CI, Kim MJ, Chung EK, Lee HI, Jang CG, Bae JW, Lee SY (2012) CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy korean subjects. Eur J Clin Pharmacol 68(2):149\u2013154. https:\/\/doi.org\/10.1007\/s00228-011-1098-0","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1448_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/JCP.0b013e3182a608a2","volume":"34","author":"CI Choi","year":"2014","unstructured":"Choi CI, Bae JW, Lee YJ, Lee HI, Jang CG, Lee SY (2014) Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. J Clin Psychopharmacol 34(1):139\u2013142. https:\/\/doi.org\/10.1097\/JCP.0b013e3182a608a2","journal-title":"J Clin Psychopharmacol"},{"key":"1448_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/PGPM.S226200","volume":"12","author":"E Chow","year":"2019","unstructured":"Chow E, Poon EW, Fok BS, Chan JC, Tomlinson B (2019) CYP2C19*2 polymorphism is associated with impaired oral clearance of gliclazide in healthy chinese. Pharmgenomics Pers Med 12:397\u2013401. https:\/\/doi.org\/10.2147\/PGPM.S226200","journal-title":"Pharmgenomics Pers Med"},{"issue":"12","key":"1448_CR17","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2337\/dc21-1152","volume":"44","author":"AY Dawed","year":"2021","unstructured":"Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, Etheridge A, Innocenti F, Xu F, Li JH, Beulens JW, van der Heijden AA, Slieker RC, Chang YC, Mercader JM, Kaur V, Witte JS, Lee MTM, Kamatani Y, Momozawa Y, Kubo M, Palmer CNA, Florez JC, Hedderson MM, \u2019t Hart LM, Giacomini KM, Pearson ER (2021) Genome-wide Meta-analysis identifies genetic Variants Associated with Glycemic Response to Sulfonylureas. Diabetes Care 44(12):2673\u20132682. https:\/\/doi.org\/10.2337\/dc21-1152","journal-title":"Diabetes Care"},{"issue":"4","key":"1448_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1365-2125.2007.02943.x","volume":"64","author":"DJ Elliot","year":"2007","unstructured":"Elliot DJ, Suharjono, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO (2007) Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol 64(4):450\u2013457. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02943.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1448_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jpba.2006.05.003","volume":"42","author":"SM Foroutan","year":"2006","unstructured":"Foroutan SM, Zarghi A, Shafaati A, Khoddam A (2006) Application of monolithic column in quantification of gliclazide in human plasma by liquid chromatography. J Pharm Biomed Anal 42(4):513\u2013516. https:\/\/doi.org\/10.1016\/j.jpba.2006.05.003","journal-title":"J Pharm Biomed Anal"},{"issue":"12","key":"1448_CR20","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00228-011-1078-4","volume":"67","author":"O G\u00f6kalp","year":"2011","unstructured":"G\u00f6kalp O, Gunes A, Cam H, Cure E, Ayd\u0131n O, Tamer MN, Scordo MG, Dahl ML (2011) Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol 67(12):1223\u20131229. https:\/\/doi.org\/10.1007\/s00228-011-1078-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1448_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2125.2005.02379.x","volume":"60","author":"A Holstein","year":"2005","unstructured":"Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockm\u00f6ller J, Kirchheiner J (2005) Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 60(1):103\u2013106. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02379.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1448_CR22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s12272-021-01363-1","volume":"44","author":"EH Jung","year":"2021","unstructured":"Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Arch Pharm Res 44(12):1109\u20131119. https:\/\/doi.org\/10.1007\/s12272-021-01363-1","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1448_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s12272-016-0861-2","volume":"40","author":"SH Kim","year":"2017","unstructured":"Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW, Lee YJ, Jang CG, Lee SY (2017) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch Pharm Res 40(3):382\u2013390. https:\/\/doi.org\/10.1007\/s12272-016-0861-2","journal-title":"Arch Pharm Res"},{"issue":"7","key":"1448_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12272-021-01346-2","volume":"44","author":"YH Kim","year":"2021","unstructured":"Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Arch Pharm Res 44(7):713\u2013724. https:\/\/doi.org\/10.1007\/s12272-021-01346-2","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1448_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12272-021-01366-y","volume":"45","author":"NT Kim","year":"2022","unstructured":"Kim NT, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2022) Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy korean subjects. Arch Pharm Res 45(2):114\u2013121. https:\/\/doi.org\/10.1007\/s12272-021-01366-y","journal-title":"Arch Pharm Res"},{"issue":"4","key":"1448_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1067\/mcp.2002.122476","volume":"71","author":"J Kirchheiner","year":"2002","unstructured":"Kirchheiner J, Brockm\u00f6ller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71(4):286\u2013296. https:\/\/doi.org\/10.1067\/mcp.2002.122476","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1448_CR27","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2165\/00003088-200544120-00002","volume":"44","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockm\u00f6ller J (2005) Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44(12):1209\u20131225. https:\/\/doi.org\/10.2165\/00003088-200544120-00002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1448_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00228-014-1641-x","volume":"70","author":"J Klen","year":"2014","unstructured":"Klen J, Dol\u017ean V, Jane\u017e A (2014) CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol 70(4):421\u2013428. https:\/\/doi.org\/10.1007\/s00228-014-1641-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1448_CR29","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1007\/s12272-015-0580-0","volume":"38","author":"YJ Lee","year":"2015","unstructured":"Lee YJ, Byeon JY, Kim YH, Kim SH, Choi CI, Bae JW, Sohn UD, Jang CG, Lee J, Lee SY (2015) Effects of CYP2C9*1\/*3 genotype on the pharmacokinetics of flurbiprofen in korean subjects. Arch Pharm Res 38(6):1232\u20131237. https:\/\/doi.org\/10.1007\/s12272-015-0580-0","journal-title":"Arch Pharm Res"},{"issue":"11","key":"1448_CR30","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00228-018-2522-5","volume":"74","author":"HI Lee","year":"2018","unstructured":"Lee HI, Byeon JY, Kim YH, Lee CM, Choi CI, Jang CG, Bae JW, Lee YJ, Lee SY (2018) Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. Eur J Clin Pharmacol 74(11):1417\u20131426. https:\/\/doi.org\/10.1007\/s00228-018-2522-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1448_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12272-022-01394-2","volume":"45","author":"CM Lee","year":"2022","unstructured":"Lee CM, Kang P, Cho CK, Park HJ, Lee YJ, Bae JW, Choi CI, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes. Arch Pharm Res 45(6):433\u2013445. https:\/\/doi.org\/10.1007\/s12272-022-01394-2","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1448_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","volume":"69","author":"A Li-Wan-Po","year":"2010","unstructured":"Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 69(3):222\u2013230. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03578.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1448_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1067\/mcp.2002.127495","volume":"72","author":"M Niemi","year":"2002","unstructured":"Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivist\u00f6 KT (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72(3):326\u2013332. https:\/\/doi.org\/10.1067\/mcp.2002.127495","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1448_CR34","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2217\/pgs.09.96","volume":"10","author":"G Ragia","year":"2009","unstructured":"Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG (2009) Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10(11):1781\u20131787. https:\/\/doi.org\/10.2217\/pgs.09.96","journal-title":"Pharmacogenomics"},{"issue":"4","key":"1448_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1515\/dmpt-2022-0131","volume":"37","author":"G Ragia","year":"2022","unstructured":"Ragia G, Atzemian N, Maslarinou A, Manolopoulos VG (2022) SLCO1B1 c.521T>C gene polymorphism decreases hypoglycemia risk in sulfonylurea-treated type 2 diabetic patients. Drug Metab Pers Ther 37(4):347\u2013352. https:\/\/doi.org\/10.1515\/dmpt-2022-0131","journal-title":"Drug Metab Pers Ther"},{"issue":"12","key":"1448_CR36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3109\/00498259509061922","volume":"25","author":"A Rieutord","year":"1995","unstructured":"Rieutord A, Stupans I, Shenfield GM, Gross AS (1995) Gliclazide hydroxylation by rat liver microsomes. Xenobiotica 25(12):1345\u20131354. https:\/\/doi.org\/10.3109\/00498259509061922","journal-title":"Xenobiotica"},{"issue":"2","key":"1448_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/clpt.2011.132","volume":"90","author":"SA Scott","year":"2011","unstructured":"Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR (2011) Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90(2):328\u2013332. https:\/\/doi.org\/10.1038\/clpt.2011.132","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1448_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2710.2009.01134.x","volume":"35","author":"H Shao","year":"2010","unstructured":"Shao H, Ren XM, Liu NF, Chen GM, Li WL, Zhai ZH, Wang DW (2010) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy chinese Han volunteers. J Clin Pharm Ther 35(3):351\u2013360. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01134.x","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"1448_CR39","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s12272-020-01294-3","volume":"43","author":"HB Shin","year":"2020","unstructured":"Shin HB, Jung EH, Kang P, Lim CW, Oh KY, Cho CK, Lee YJ, Choi CI, Jang CG, Lee SY, Bae JW (2020) ABCB1 c.2677G>T\/c.3435\u00a0C>T diplotype increases the early-phase oral absorption of losartan. Arch Pharm Res 43(11):1187\u20131196. https:\/\/doi.org\/10.1007\/s12272-020-01294-3","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1448_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113. https:\/\/doi.org\/10.1016\/j.clpt.2005.10.002","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1448_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.diabres.2005.09.019","volume":"72","author":"K Suzuki","year":"2006","unstructured":"Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M (2006) Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 72(2):148\u2013154. https:\/\/doi.org\/10.1016\/j.diabres.2005.09.019","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"1448_CR42","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s12272-022-01403-4","volume":"45","author":"SS Whang","year":"2022","unstructured":"Whang SS, Cho CK, Jung EH, Kang P, Park HJ, Lee YJ, Choi CI, Bae JW, Kim HS, Jang CG, Lee SY (2022) Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes. Arch Pharm Res 45(8):584\u2013595. https:\/\/doi.org\/10.1007\/s12272-022-01403-4","journal-title":"Arch Pharm Res"},{"issue":"7","key":"1448_CR43","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/sj.bjp.0707685","volume":"153","author":"H Xu","year":"2008","unstructured":"Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ (2008) Effects of St John\u2019s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 153(7):1579\u20131586. https:\/\/doi.org\/10.1038\/sj.bjp.0707685","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1448_CR44","doi-asserted-by":"publisher","first-page":"10994","DOI":"10.1038\/s41598-018-29351-4","volume":"8","author":"F Yang","year":"2018","unstructured":"Yang F, Xiong X, Liu Y, Zhang H, Huang S, Xiong Y, Hu X, Xia C (2018) CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide. Sci Rep 8(1):10994. https:\/\/doi.org\/10.1038\/s41598-018-29351-4","journal-title":"Sci Rep"},{"issue":"4","key":"1448_CR45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.clpt.2005.06.006","volume":"78","author":"OQ Yin","year":"2005","unstructured":"Yin OQ, Tomlinson B, Chow MS (2005) CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in chinese subjects. Clin Pharmacol Ther 78(4):370\u2013377. https:\/\/doi.org\/10.1016\/j.clpt.2005.06.006","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1448_CR46","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/jdi.12486","volume":"7","author":"W Zeng","year":"2016","unstructured":"Zeng W, Guo Y, Chen P, Liu Z, Chen D, Han C (2016) CYP2C9*3 variant is associated with antidiabetes efficacy of gliclazide in chinese type 2 diabetes patients. J Diabetes Investig 7(5):764\u2013768. https:\/\/doi.org\/10.1111\/jdi.12486","journal-title":"J Diabetes Investig"},{"issue":"1","key":"1448_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1365-2125.2007.02846.x","volume":"64","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Si D, Chen X, Lin N, Guo Y, Zhou H, Zhong D (2007) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in chinese subjects. Br J Clin Pharmacol 64(1):67\u201374. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02846.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1448_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41(2):89\u2013295. https:\/\/doi.org\/10.1080\/03602530902843483","journal-title":"Drug Metab Rev"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-023-01448-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-023-01448-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-023-01448-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T05:14:49Z","timestamp":1683177289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-023-01448-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1007\/s12272-023-01448-z","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}